Clinical Trial: Brain Imaging and Immune Changes During Remibrutinib Treatment in Multiple Sclerosis.

U.S., Aug. 12 -- ClinicalTrials.gov registry received information related to the study (NCT07758270) titled 'Brain Imaging and Immune Changes During Remibrutinib Treatment in Multiple Sclerosis.' on Aug. 05.

Brief Summary: REDEFINE-MS is a research study for people with relapsing multiple sclerosis (MS) who are participating in the RESHAPE-MS trial. The study aims to better understand how remibrutinib affects inflammation in the brain and spinal cord by using PET imaging, MRI scans, blood samples, and cerebrospinal fluid (CSF) samples collected before treatment and again six months later. [REDEFINE\_p...2026\_clean | Word] The main question the study is trying to answer is whether remibrutinib changes immune activity and inflammation in pe...